Monitoring of safety using favipiravir: risk management of adverse drug reactions in clinical practice
Global experience with the clinical use of favipiravir is very limited. Its safety is for further study. Prevention of teratogenic effects (mandatory pregnancy test before starting therapy, compliance with effective contraception by both women and men), control of the level of uric acid, transaminas...
Saved in:
Main Authors: | Yu. Yu. Kiselev (Author), A. V. Matveev (Author), K. B. Mirzaev (Author), D. A. Sychev (Author) |
---|---|
Format: | Book |
Published: |
Izdatelstvo OKI,
2020-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Current and future use of favipiravir in patients with COVID-19
by: A. V. Matveev, et al.
Published: (2020) -
What are the indications for combined use of hydroxychloroquine and lopinavir/ritonavir, and how should treatment safety monitoring be performed?
by: Yu. Yu. Kiselev, et al.
Published: (2020) -
Genetic Risk Factors for Adverse Drug Reactions
by: D. A. Sychev, et al.
Published: (2022) -
Patients' Pharmacogenetic Characteristics and the Risk of Adverse Reactions to Non-steroidal Anti-inflammatory Drugs: Case Reports
by: A. S. Zhiryakova, et al.
Published: (2024) -
Adjusting the role of hydroxychloroquine with or without azithromycin in patients with COVID-19
by: V. A. Otdelenov, et al.
Published: (2020)